Aerosolized Versus Intravenous Colistin-based Antimicrobial Regimens in Hospitalized COVID-19 Patients With Bacterial Coinfection: A Randomized Controlled Trial
NCT ID: NCT05689229
Last Updated: 2023-01-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
128 participants
INTERVENTIONAL
2021-08-03
2021-12-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Aerosolised Colistin in Ventilator Associated Pneumonia
NCT02683603
Comparative Study of Clinical Outcomes and Safety Between Colistin and Tigecycline
NCT06893835
Different Dosing Strategies of Colistin in Multidrug-Resistant Gram-Negative Bacilli Infections
NCT06843668
Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections
NCT05210387
Intravenous Colistin Versus Intravenous Colistin Plus Nebulized Colistin in VAP Due MDR Acinetobacter Baumannii
NCT00645723
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Colistin IV
Colistin
COVID-19 patients with secondary gram-negative bacterial infections receive colistin IV or aerosolized
Colistin Aerosolized
Colistin
COVID-19 patients with secondary gram-negative bacterial infections receive colistin IV or aerosolized
Control
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Colistin
COVID-19 patients with secondary gram-negative bacterial infections receive colistin IV or aerosolized
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* patients less than 18 years
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beni-Suef University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hasnaa Osama
Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital
Banī Suwayf, Beni Suweif Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BSU-22006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.